NEW YORK, April 4, 2018 /PRNewswire/ --
WallStEquities.com strives to bring the best free research to the investmentcommunity. Today we are offering reports on OMER, ARGS, ARRY, and AUPH which can be accessed for free by signing up to www.wallstequities.com/registration. For today, WallStEquities.com covers the Biotech industry, which consists of companies that
Seattle, Washington-based Omeros Corp.'s stock finished Tuesday's session 12.60% higher at $12.15 with a total trading volume of 990,978 shares. Over the last month, the Company's shares have advanced 21.38%. The stock is trading below its 50-day moving average by 4.83%. Moreover, shares of Omeros, which discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system, have a Relative Strength Index (RSI) of 49.94.
On March 23rd, 2018, research firm Wedbush downgraded the Company's stock rating from 'Outperform' to 'Neutral' while revising its previous target price from $47 a share to $19 a share. Get the full research report on OMER for free by clicking below at: www.wallstequities.com/registration/?symbol=OMER
Shares in Durham, North Carolina headquartered Argos Therapeutics Inc. plummeted 16.67%, ending yesterday's session at $0.75 with a total trading volume of 584,910 shares. The stock is trading 50.87% below its 50-day moving average. Shares of the Company, which focuses on the development and commercialization of personalized immunotherapies for the treatment of cancer and infectious diseases, have an RSI of 14.29.
On April 02nd, 2018, Argos Therapeutics reported its results for Q4 and full year 2017. For Q4 2017, revenue was $1.7 million, interest expense was $0.2 million, and net loss was $1.9 million. For the full year, revenue was $1.9 million, interest expense was $1.3 million, and net loss was $40.6 million. As of December 31st, 2017, cash and cash equivalents totaled $15.2 million. Find your free research report on ARGS at: www.wallstequities.com/registration/?symbol=ARGS
On Tuesday, Boulder, Colorado headquartered Array BioPharma Inc.'s stock rose 0.85%, to close the day at $15.39. A total volume of 2.74 million shares was traded. The Company's shares have advanced 20.23% in the previous three months and 72.15% over the past year. The stock is trading 28.51% above its 200-day moving average. Additionally, shares of Array BioPharma, which focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and Asia/Pacific, have an RSI of 39.61.
On March 22nd, 2018, Array BioPharma announced that detailed results of its pivotal Phase-3 COLUMBUS trial for the treatment of patients with BRAF-mutant advanced, unresectable or metastatic melanoma were published in The Lancet Oncology. In the analysis of the primary endpoint, the median progression-free survival for patients treated with the combination of encorafenib, 450 mg daily, plus binimetinib, 45 mg twice daily (COMBO450), was 14.9 months versus 7.3 months for patients treated with vemurafenib, 960 mg twice daily. Sign up today for the free research report on ARRY at: www.wallstequities.com/registration/?symbol=ARRY
Shares in Victoria, Canada headquartered Aurinia Pharmaceuticals Inc. ended the day 2.96% higher at $5.21. A total volume of 510,556 shares was traded. The stock has gained 15.01% in the previous three months. The Company's shares are trading below their 50-day moving average by 3.04%. Furthermore, shares of Aurinia Pharma, which engages in the development of a therapeutic drug to treat autoimmune diseases in Canada, have an RSI of 46.60.
On March 15th, 2018, Aurinia Pharma released its financial results for Q4 and year ended December 31st, 2017. For Q4 2017, consolidated net loss was $3.3 million; R&D expenses were $8.7 million; and corporate, administration and business development expense was $3.1 million. For the full year, consolidated net loss was $70.9 million; R&D expenses were $33.9 million; and corporate, administration and business development expense was $12.1 million.
On March 16th, 2018, research firm Cantor Fitzgerald reiterated its 'Overweight' rating on the Company's stock with an increase of the target price from $14 a share to $16 a share. Wall St. Equities' research coverage also includes the downloadable free report on AUPH at: www.wallstequities.com/registration/?symbol=AUPH
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: email@example.com Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/free-research-reports-on-these-biotech-stocks----omeros-argos-therapeutics-array-biopharma-and-aurinia-pharma-300624148.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Lazy eye or amblyopia occurs when sight in one eye is less than the other in early childhood due to ...
Tracheal or windpipe cancer is a rare cancer and its cause is unclear. The most common squamous ...
Tecovirimat can be used to treat smallpox disease in adult and pediatric patients who weigh at ...View All